OncoDNA, MyNEO partner on personalized cancer vaccines

By The Science Advisory Board staff writers

April 7, 2021 -- OncoDNA and MyNEO will collaborate on the production of personalized cancer vaccines for patients who have run out of treatment options.

The companies will use their sequencing and bioinformatics technologies to identify and select the most effective neoantigens to target in a patient. OncoDNA will perform whole genome and whole transcriptome sequencing, and MyNEO will handle the advanced interpretation of the sequenced data and design the vaccine construct. Eligible patients would receive tailor-made vaccines and follow-up by monitoring circulating tumor DNA after inoculation using OncoDNA's OncoFollow liquid biopsy platform.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.